drugset / Trial / NCT06533553
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Timeline
- Start
- 2024-07-09
- Primary completion
- 2025-10
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexpramipexole | Small molecule | 150 mg | Oral |